Subscribe
People
3 min read

Pet insurance's growth problem isn't demand, it's distribution — and adoro just hired for the fix

adoro Pet Insurance hired Scott Taylor, formerly president of Spot, as Chief Business Development Officer to build employer and partner channels. The move is a bet that pet insurance's growth bottleneck is distribution, not demand.

Written by
The Underbite
Published on
June 12, 2026
Pet insurance's growth problem isn't demand, it's distribution — and adoro just hired for the fix

The direct-to-consumer pet insurance playbook, buy clicks, convert shoppers, eat the acquisition cost, is getting expensive enough that challengers are routing around it. The latest signal: a fast-growing insurer poached the former president of Spot to build out employer benefits and partner channels instead. The hire is small. What it says about where pet insurance growth comes from next is not.

adoro names Spot's former president to run benefits distribution

Scott Taylor has joined adoro Pet Insurance as Chief Business Development Officer, where he'll lead the company's employee benefits and partnerships strategy and push to expand access through benefit brokers and partners.

Taylor brings more than twenty years in insurance business development, including over a decade focused solely on pet insurance. He was most recently president of Spot Pet Insurance, one of the larger DTC-era brands in the category.

The mandate is explicit in the title and the framing. "Scott understands how to build distribution at scale," said adoro co-founder and CEO Gavin Friedman. adoro, which launched across 28 states, is betting its next leg of growth comes through channels, not clicks.

Why pet insurers are abandoning the DTC playbook

Hiring a business-development chief whose remit is employer benefits and partnerships is a strategy statement. It says the company believes the cheapest path to a new policyholder runs through an employer's benefits menu or a partner's point of sale, not a search ad.

The economics explain the shift. DTC pet insurance has always carried punishing acquisition costs, because you're marketing a considered purchase to individuals one at a time. Embedded and benefits distribution flips that. A single employer relationship puts adoro in front of an entire workforce, and a point-of-sale partner reaches the buyer at the exact moment they acquire the pet. Lower CAC, higher intent, better persistency.

That Taylor comes from a DTC-era brand sharpens the read. When an executive who helped scale a direct-to-consumer insurer moves to build the benefits channel, it's a tell about where the people closest to the unit economics think the next dollar of efficient growth lives.

This isn't a one-company move. The same day adoro announced the hire, Odie and Haven announced a partnership to expand embedded pet insurance through what they called high-trust distribution channels. Two separate distribution plays, both built on embedded and partnership models, both landing on the same day. The pattern is the story.

For incumbents, the competitive question is exposure. Brands that built their books primarily on DTC, Trupanion, Lemonade's pet line, and the various Spot-era challengers, are most at risk if the channel of record shifts to the employer and the point of sale. Owning the benefits relationship is a different muscle than owning the paid-search funnel, and it favors whoever moves first to lock up brokers and partners.

For pet businesses outside insurance, there's a read-through. The benefits channel is becoming a contested distribution surface for pet products and services generally. Whoever controls the employer relationship controls a low-cost path to the pet owner, and insurance is simply the first category to chase it hard.

What embedded distribution does to the incumbents

The next signals to watch are the deals behind the hire. A CBDO appointment is the setup. The proof is the broker rosters, employer wins, and embedded partnerships that show up over the next two to three quarters.

The benefits land-grab: Watch which insurers announce employer and broker partnerships through the back half of 2026. Benefits enrollment cycles are seasonal, and the players signing brokers now are positioning for open-enrollment season.

The CAC disclosure gap: Private pet insurers rarely publish acquisition costs. If embedded distribution delivers the economics its backers claim, expect the winners to start hinting at CAC advantages in their messaging. That's the tell that the model is working.

Pet insurance penetration in the U.S. still sits in the low single digits, far below the U.K. and other mature markets. The gap has always been framed as a demand problem. adoro is betting it's a distribution one.

Source: adoro Pet Insurance via PR Newswire

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles